IP Verse

Actavis competitive analysis

Explore patent oppositions filed by Actavis against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Aug 27, 2026

Patent Number	Title	Applicant	Opposition Date
EP2036557	Antitumor Agent For Thyroid Cancer	EISAI R&D MANAGEMENT	Jul 18, 2016
EP2318365	Novel Polymorphic Forms Of Perindopril (L)-Arginine And Process For The Preparation Thereof	MATRIX LABORATORIES	May 11, 2016
EP2322174	Combined Use Of Valsartan And Calcium Channel Blockers For Therapeutic Purposes	NOVARTIS	Mar 3, 2016
EP2269603	Treatment Of Solid Tumours With Rapamycin Derivatives	NOVARTIS	Feb 22, 2016
EP2801355	Controlled Release Pharmaceutical Compositions Comprising A Fumaric Acid Ester	FORWARD PHARMA	Feb 19, 2016
EP2266573	Fulvestrant Formulation	ASTRAZENECA	Feb 16, 2016
EP2647399	Inhaler	BOEHRINGER INGELHEIM	Jan 29, 2016
EP1773293	Compositions And Methods For Treating Central Precocious Puberty	ENDO PHARMACEUTICALS SOLUTIONS	Jan 15, 2016
EP2318419	Boronate Ester Compounds And Pharmaceutical Compositions Thereof	MILLENNIUM PHARMACEUTICALS	Jan 8, 2016
EP1845961	Prevention And Treatment Of Thromboembolic Disorders	BAYER	Jan 6, 2016

Discover the latest PTAB cases involving Actavis, highlighting their recent legal challenges and patent disputes.

Last updated on: Aug 30, 2026

Proceeding Number	Filing Date	Petitioner	Respondent	Status
Get alerts for PTAB Cases involving Actavis
IPR2017-01946	Aug 15, 2017	ACTAVIS ELIZABETH	NOVARTIS PHARMACEUTICALS	Final Written Decision
IPR2017-01100	Apr 4, 2017	ACTAVIS	ABRAXIS BIOSCIENCE	Institution Denied
IPR2017-01101	Apr 4, 2017	ACTAVIS	ABRAXIS BIOSCIENCE	Terminated-Settled
IPR2017-01101	Apr 4, 2017	ACTAVIS	SOON SHIONG DESAI	Terminated-Settled
IPR2017-01103	Apr 4, 2017	ACTAVIS	ABRAXIS BIOSCIENCE	Terminated-Settled
IPR2017-01103	Apr 4, 2017	ACTAVIS	SOON SHIONG DESAI	Terminated-Settled
IPR2017-01104	Apr 4, 2017	ACTAVIS	ABRAXIS BIOSCIENCE	Terminated-Settled
IPR2017-01104	Apr 4, 2017	ACTAVIS	SOON SHIONG DESAI	Terminated-Settled
IPR2017-00853	Feb 8, 2017	ACTAVIS LABORATORIES FL	BELLDEGRUM AUERBACH	Final Written Decision
IPR2017-00853	Feb 8, 2017	ACTAVIS LABORATORIES FL	JANSSEN ONCOLOGY	Final Written Decision

IP litigation analysis comparing Actavis with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Aug 27, 2026

Company	Oppositions Filed	Oppositions Faced	PTAB Cases Filed	PTAB Cases Faced
ACTAVIS GROUP PTC EHF	23	-	-	-
ATNAHS PHARMA UK	-	14	-	-
EURO CELTIQUE	-	73	-	-
PROGENICS PHARMACEUTICALS	-	7	1	3